On June 10, 2021 Ascentage Pharma, a Suzhou company, reported promising data from an early test of its Bcl-2 inhibitor in hematologic malignancies. Lisaftoclax (APG-2575) showed an objective response rate of 80% in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and other hematologic malignancies (Press release, Ascentage Pharma, JUN 10, 2021, View Source [SID1234583925]). Previously, patients had received a median of two treatments for their disease. The results were reported in an oral presentation at the 57th ASCO (Free ASCO Whitepaper) Annual Meeting, one of four Ascentage presentations at the meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!